Please set your featured image
OGT buys Cytocell
Oxford Gene Technology (OGT), provider of innovative genetics research solutions based at Begbroke Science Park, has announced the acquisition of Cambridge-based Cytocell Limited (Cytocell), a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer.
The acquisition expands OGT’s genomic medicine offering, and entry into the FISH product market. It improves their product offering for their North American customers and strengthens their distributor network worldwide. Dr Martin Lawrie, MD of Cytocell, joins the OGT board.
Dr Mike Evans, CEO of OGT said, “The acquisition of Cytocell underscores our commitment to becoming a global leader in genomic medicine. Cytocell brings to the OGT Group, innovative DNA technology, an excellent team and a strong brand with a reputation for high-quality FISH products. This is a great opportunity to add to our portfolio of class-leading technologies and position ourselves for growth across new geographical markets and customer application areas.”
Dr Martin Lawrie, Managing Director of Cytocell said, “This is an excellent strategic fit for both Cytocell and OGT. The aim is to continue to develop and produce our world-renowned FISH-based diagnostic products from our facility in Cambridge and take advantage of OGT’s established sales and marketing infrastructure in the US and Europe as well as its innovative science to expand the markets for these products. We very much look forward to being part of the OGT Group.”
For more information, please contact:
Oxford Gene Technology